HK Stock Market Move | NEAUTUS (02206), a leading traditional Chinese medicine decoction pieces company, surged over 30% to a new high, rising more than 1.85 times from its IPO price.

date
14:54 19/11/2026
avatar
GMT Eight
Xinhehua (02206) surged over 30% against the market trend, reaching a high of HK$114.8, a new listing high, up more than 1.85 times from its IPO price of HK$40.2.
NEAUTUS (02206) surged over 30% against the market trend, hitting a new listing high of HK$114.8, up more than 1.85 times from its IPO price of HK$40.2. As of press time, it was up 29.16% at HK$110.3, with turnover of HK$41.0075 million. NEAUTUS is a core supplier of large-scale traditional Chinese medicine decoction pieces in China. It offers two major categories of productsordinary TCM decoction pieces and toxic decoction piecestotaling more than 770 types and over 4,900 products, and serves more than 1,000 customers in China, including hospitals, medical institutions, and large chain pharmacies. Based on 2025 revenue from sales of TCM decoction piece products, the company ranks No. 2 in the industry nationwide. In terms of performance, the company's revenue was RMB1.146 billion, RMB1.249 billion, and RMB1.335 billion in 2023, 2024, and 2025, respectively. Revenue for the first four months of this year was RMB432 million, up 12.9% year on year; net profit was RMB33.9 million, a sharp increase of 63.8% year on year; gross margin recovered from 17.1% in 2024 to 21.8%. Profit growth far outpaced revenue growth, mainly due to lower costs of core raw materials such as Coptis chinensis, Fritillaria cirrhosa, and Pinellia ternata processed with alum, as well as the economies of scale brought by increased volume from centralized procurement.